NCT05655520

A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Huntington's Disease

A Phase 3, Multicenter, Open-label Safety Study to Evaluate the Long-term Safety and Tolerability of SAGE-718 in Participants With Huntington's Disease

• Status: Terminated
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 153 (actual)
• Sponsor: Supernus Pharmaceuticals, Inc. · Industry
• Sex: All
• Age: 25 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The primary purpose of the study is to evaluate the safety and tolerability of SAGE-718 softgel lipid capsule in participants with Huntington's Disease (HD)

Conditions

• Huntington's Disease

Interventions

Type	Name	Description
DRUG	SAGE-718	Oral softgel lipid capsules

Timeline

• Start date: 2022-12-14
• Primary completion: 2025-01-20
• Completion: 2025-01-20
• First posted: 2022-12-19
• Last updated: 2025-12-17
• Results posted: 2025-12-17

Locations

43 sites across 4 countries: United States, Australia, Canada, United Kingdom

Regulatory

• FDA-regulated drug study